Amplexd Therapeutics, a Gaithersburg, MD-based clinical stage patient-scientist-led biotech company, raised USD2M in funding.
Backers included an Asia-based life sciences focused family office.
The company intends to use the funds to finalize the development and IND submissions ahead of first-in-human clinical trials, expected to commence later this year.
Led by CEO Alia Rahman, Amplexd Therapeutics is developing two low-cost, non-invasive therapies for the treatment of cervical intraepithelial neoplasia (cervical precancer). The first is an intravaginal suppository for low-grade CIN, and the second is a photodynamic therapy (PDT) system for high-grade CIN, each designed to selectively target neoplastic cells. These treatments are designed to both modernize the paradigm for women in developed nations by sparing the need for invasive surgeries, as well as provide access to potentially lifesaving care for those in low and middle-income regions.
FinSMEs
20/05/2024